Bionano Genomics (BNGO) Asset Writedowns and Impairment (2017 - 2024)

Bionano Genomics has reported Asset Writedowns and Impairment for 6 years, with the latest figure at -$417000.0 in Q4 2024.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to -$417000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $6.8 million (down 6.2% YoY) and the FY2024 annual result came in at $7.2 million, changed N/A from the prior year.
• Asset Writedowns and Impairment fell to -$417000.0 in Q4 2024 per BNGO's latest filing, from $7.2 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $7.2 million in Q3 2024 and troughed at -$1.2 million in Q4 2020.
• A 3-year average of $996625.0 and a median of $390000.0 in 2020 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 317.71% in 2020, down 317.71% in 2020.
• Over 3 years, Asset Writedowns and Impairment stood at -$1.2 million in 2020, then surged by 150.99% to $616000.0 in 2022, then tumbled by 167.69% to -$417000.0 in 2024.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$417000.0, $7.2 million, and $448000.0 for Q4 2024, Q3 2024, and Q1 2024 respectively.